

24/10/2023

Dear Healthcare Professional,

RE: DISCONTINUATION OF MS MONO®, OXYNORM® CAPSULES AND SEVREDOL® TABLETS

After careful consideration, and having informed the Health Authorities, Mundipharma Pty Limited (Mundipharma) will no longer supply the following products from its pharmaceutical portfolio:

- OxyNorm[®] capsules 5 mg, 10mg & 20mg (oxycodone hydrochloride) AUST R 74145, 74143, 74141
- MS Mono[®] capsules 30mg, 60mg, 90mg & 120mg (modified release morphine sulfate) AUST R 74156, 74154, 74152, 74150
- Sevredol[®] tablets 10mg & 20 mg (morphine sulfate) AUST R 47543, 214089

It is important to note that this is a global decision, based on the complexity of continuing to provide these products. Mundipharma is taking steps to make robust efficiency changes at our global manufacturing site in order to strengthen supply lines and guarantee future supply of our remaining pain medications.

Given current demand, we anticipate the products will be discontinued from the market at varying timepoints as illustrated in the table as follows:

MS Mono® capsules 30mg	September 2024
MS Mono® capsules 60mg	October 2024
MS Mono® capsules 90mg	August 2024
MS Mono [®] capsules 120mg	September 2024
Sevredol® tablets 10mg	July 2024
Sevredol® tablets 20mg	April 2024
OxyNorm® capsules 5mg	March 2025
OxyNorm® capsules 10mg	June 2024
OxyNorm [®] capsules 20mg	March 2025

Please refer to the <u>TGA Medicine Shortage reports database</u> for the most current discontinuation date as these may be subject to change based on any fluctuations in current demand.

Should you have any further questions, please contact Mundipharma Medical Information (1800 188 009 or medinfo@mundipharma.com.au).

Steven Van den Bossche

DIRECTOR

Mundipharma Pty Limited